Peyronie’s 3 Ts Protocol Offers Structure, but Not Proof of Regeneration
A new commentary on the proposed 3 Ts Protocol for Peyronie’s disease draws a sharp line between a carefully organized treatment framework and actual evidence of biologic repair. The protocol combines daily tadalafil, plaque tunneling with intralesional biologic injections, and daily penile traction therapy into a sequential regimen aimed at restoring function and structure. In a field where nonsurgical care often relies on fragmented practice patterns, that level of procedural standardization is appealing.
The problem is evidentiary, not conceptual. The protocol assembles multiple plausible interventions, but plausibility alone does not establish that the combination is synergistic, regenerative, or superior to any single component. Each step may make sense in isolation, yet the full sequence has not been tested in a controlled clinical cohort with prespecified outcomes, comparator arms, or safety reporting. In practical terms, a protocol can be reproducible without being proven.
Mechanistic Logic Outpaces Clinical Data
The commentary acknowledges that daily tadalafil, intralesional platelet-rich plasma or hyaluronic acid, plaque tunneling, and penile traction each have some literature behind them. Still, the evidentiary strength of those elements varies widely, and the leap from isolated signals to a multimodal regeneration strategy is substantial. The central concern is that the protocol appears to stack one mechanistic hypothesis on top of another without showing that the combination produces more than additive speculation.
This matters because treatment effect in Peyronie’s disease is notoriously difficult to interpret when several interventions are delivered at once. If curvature improves, the change could reflect traction, intralesional therapy, spontaneous fluctuation in the active phase, tadalafil exposure, or the mechanical consequences of tunneling. Without factorial testing or component-controlled studies, attribution remains impossible. The result is a therapeutic package whose internal logic may be attractive while its clinical contribution remains unresolved.
Daily Tadalafil Sits on Conflicting Ground
The commentary also challenges the way daily tadalafil is framed. One retrospective comparative analysis cited in support of the approach suggested that low-dose tadalafil may reduce curvature progression in acute disease. Another retrospective cohort, published in the same journal, found that phosphodiesterase type 5 inhibitors did not prevent curvature progression, although they did shorten penile pain duration. Those findings do not point in the same direction.
That divergence weakens any attempt to present tadalafil as a settled antifibrotic strategy in this setting. PDE type 5 inhibition may plausibly influence cavernosal hemodynamics, endothelial function, and tissue remodeling, but the clinical literature remains mixed. A therapy that shortens pain without changing curvature progression is not interchangeable with one that reverses fibrosis, and the distinction matters when the drug is embedded in a broader restoration protocol.
Tunneling and Biologic Delivery Need Direct Validation
The most distinctive part of the protocol may be plaque tunneling followed by biologic injection after low-intensity shockwave therapy. The proposed sequence relies on the idea that shockwave exposure transiently increases tissue permeability and creates a delivery window for intralesional agents. The commentary argues that the cited evidence does not directly show that effect in penile plaque tissue or prove enhanced penetration of biologics into the tunica albuginea.
This is not a minor mechanistic quibble. The entire delivery concept depends on the assumption that timing shockwave treatment immediately before injection changes tissue behavior in a clinically useful way. If the permeability effect is not real, or if it does not translate into better intralesional distribution, the rationale for this sequencing weakens substantially. Until direct experimental work confirms the mechanism, the permeability claim should be treated as a hypothesis rather than a demonstrated biological fact.
Mechanical Injury Cuts Both Ways
A deeper inconsistency appears in the way the protocol treats trauma itself. The pathogenesis of Peyronie’s disease is usually linked to repetitive subclinical tunical injury, inflammation, and subsequent profibrotic remodeling. Yet the tunneling concept depends on deliberate needle-induced microtrauma being redirected away from fibrosis and toward repair. In other words, the same biological trigger is being cast as both the source of disease and the gateway to treatment.
That paradox does not make the protocol impossible, but it does make the mechanistic burden much heavier. Controlled trauma combined with PRP or hyaluronic acid might alter the wound-healing response, but no cited evidence shows that this response is shifted from scar formation to true tissue regeneration. The gap between injury and restoration is where the biology still has to be proven.
Fibroblasts, Extracellular Vesicles, and the Limits of Extrapolation
The commentary also pushes back on the protocol’s use of fibroblast biology and extracellular vesicle data. Corpora cavernosa fibroblasts clearly participate in penile erection physiology, and that finding broadens the view of stromal cells in erectile tissue. Even so, an active physiologic role does not automatically translate into an antifibrotic role in diseased tunica tissue.
Likewise, extracellular vesicles cannot be assumed to be protective simply because they are biologically active. The cited narrative review presents a more complex picture, with fibroblast-derived vesicles capable of reparative or deleterious effects depending on cellular origin and disease context. In Peyronie’s disease, the available literature does not justify treating fibroblast-derived vesicles as broadly antifibrotic. Some signals may be repair-oriented, others profibrotic, and the balance likely depends on the local microenvironment.
Regeneration Requires More Than Curvature Change
The commentary is especially cautious about the language of “restoration” and “regeneration.” Improvement in curvature, pain, or erectile function would be clinically meaningful, but those outcomes do not by themselves prove restored tunical architecture. True tissue regeneration would require histologic, molecular, biomechanical, or advanced imaging evidence that matrix organization has normalized, not merely that symptoms or curvature have improved.
That standard has not been met. The protocol currently stands as a hypothesis-generating framework with an unusually orderly design, not as proof of structural restoration. Its chief value may be that it creates a reproducible platform for future testing. Factorial studies could isolate the contribution of tadalafil, traction, tunneling, and biologic injection; component-controlled trials could determine whether any element is essential; and safety data could clarify whether the procedural burden is justified.
For now, the most defensible reading is straightforward. The 3 Ts Protocol is an organized attempt to bring order to a disorderly treatment space, but the language of synergy and regeneration runs ahead of the evidence. In a disease where fibrosis is the endpoint and clinical improvement can arise from several overlapping mechanisms, the field still needs comparative data before a mechanistic framework can be called a therapeutic advance.